These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Immunogenicity Following Administration of BNT162b2 and Ad26.COV2.S COVID-19 Vaccines in the Pregnant Population during the Third Trimester. Citu IM; Citu C; Gorun F; Sas I; Tomescu L; Neamtu R; Motoc A; Gorun OM; Burlea B; Bratosin F; Malita D Viruses; 2022 Feb; 14(2):. PubMed ID: 35215900 [TBL] [Abstract][Full Text] [Related]
10. Massive bullous local reaction following administration of Ad26.COV2.S COVID-19 vaccine. Montero-Menárguez J; Falkenhain-López D; Guzmán-Pérez LM; Rodríguez-Peralto JL; Tous-Romero F; Gallego-Álvarez S Int J Dermatol; 2022 May; 61(5):636-638. PubMed ID: 35049059 [No Abstract] [Full Text] [Related]
11. Assessment of neutralizing antibody responses after natural SARS-CoV-2 infection and vaccination in congolese individuals. Batchi-Bouyou AL; Djontu JC; Vouvoungui JC; Mfoutou Mapanguy CC; Lobaloba Ingoba L; Mougany JS; Boumpoutou KR; Diafouka-Kietela S; Ampa R; Ntoumi F BMC Infect Dis; 2022 Jul; 22(1):610. PubMed ID: 35831798 [TBL] [Abstract][Full Text] [Related]
12. Analysis of the Effectiveness of the Ad26.COV2.S Adenoviral Vector Vaccine for Preventing COVID-19. Corchado-Garcia J; Zemmour D; Hughes T; Bandi H; Cristea-Platon T; Lenehan P; Pawlowski C; Bade S; O'Horo JC; Gores GJ; Williams AW; Badley AD; Halamka J; Virk A; Swift MD; Wagner T; Soundararajan V JAMA Netw Open; 2021 Nov; 4(11):e2132540. PubMed ID: 34726743 [TBL] [Abstract][Full Text] [Related]
13. Association of Ad26.COV2.S COVID-19 Vaccine With Presumptive Guillain-Barré Syndrome. Li HF; Hu SM; Lv M JAMA; 2022 Jan; 327(4):392-393. PubMed ID: 35076675 [No Abstract] [Full Text] [Related]
14. Presumptive Guillain-Barré Syndrome Associated With Receipt of the Ad26.COV2.2.S COVID-19 Vaccine-Reply. Woo EJ; Dimova RB; Mba-Jonas A JAMA; 2022 Jan; 327(4):393-394. PubMed ID: 35076672 [No Abstract] [Full Text] [Related]
15. Durability of the Single-Dose Ad26.COV2.S Vaccine in the Prevention of COVID-19 Infections and Hospitalizations in the US Before and During the Delta Variant Surge. Polinski JM; Weckstein AR; Batech M; Kabelac C; Kamath T; Harvey R; Jain S; Rassen JA; Khan N; Schneeweiss S JAMA Netw Open; 2022 Mar; 5(3):e222959. PubMed ID: 35297969 [TBL] [Abstract][Full Text] [Related]
16. Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study. Hyun H; Choi MJ; Heo JY; Seo YB; Nham E; Yoon JG; Seong H; Noh JY; Cheong HJ; Kim WJ; Choi JY; Lee YJ; Lee HW; Kim SS; Kim B; Song JY J Korean Med Sci; 2022 Jul; 37(27):e210. PubMed ID: 35818701 [TBL] [Abstract][Full Text] [Related]
17. Dichotomy between the humoral and cellular responses elicited by mRNA and adenoviral vector vaccines against SARS-CoV-2. Ukey R; Bruiners N; Mishra H; Mishra PK; McCloskey D; Onyuka A; Chen F; Pinter A; Weiskopf D; Sette A; Roy J; Gaur S; Gennaro ML BMC Med; 2022 Jan; 20(1):32. PubMed ID: 35073931 [TBL] [Abstract][Full Text] [Related]
18. Comparative Effectiveness of Coronavirus Disease 2019 (COVID-19) Vaccines Against the Delta Variant. Risk M; Shen C; Hayek SS; Holevinski L; Schiopu E; Freed G; Akin C; Zhao L Clin Infect Dis; 2022 Aug; 75(1):e623-e629. PubMed ID: 35137006 [TBL] [Abstract][Full Text] [Related]